Liver treatment with immunotherapy for uveal melanoma that spread to the liver
Part of Cancer, Eyes & vision clinical trials.
This trial tests whether adding a liver-directed therapy (PHP) to a combination of two immunotherapy drugs (ipilimumab and nivolumab) works better than the immunotherapy drugs alone for people whose uveal melanoma has spread to the liver.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with uveal melanoma that has spread to the liver and confirmed by biopsy.
- You have at least one tumor in the liver that can be measured on a CT scan.
- You have not had any previous treatment for the spread of uveal melanoma, except for certain cases where a specific drug (tebentafusp) stopped working or after surgery or ablation treatments.
- You are healthy enough to undergo a procedure called percutaneous hepatic perfusion (a way to deliver chemotherapy directly to the liver).
- You agree to use effective contraception during the study and for 150 days after your last treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests immunotherapy before surgery for people with high-risk eye melanoma (uveal melanoma). You’ll get treatment to help your immune system fight the cancer, then have your eye removed. After surgery, you’ll be followed to see how well the treatment worked.
This Phase 1 trial tests a treatment using a patient’s own immune cells (TILs) plus a brief period of chemotherapy to help the immune system fight melanoma that has spread mainly to the liver. It may be an option if your melanoma has progressed after prior medicines and you have liver lesions that can be removed to make the cells.
This study tests how well the liver responds to a treatment called percutaneous hepatic perfusion with melphalan (chemotherapy delivered directly to the liver) in people with uveal melanoma that has spread to the liver. The goal is to see how the immune system reacts and if the treatment helps control the disease.
This trial tests a combination of liver-directed chemotherapy (HEPZATO KIT) with a new immunotherapy called Opdualag for people whose melanoma has spread to the liver and who have not had many prior treatments.
This trial tests using your own immune cells (TILs) to fight advanced uveal melanoma, undifferentiated pleomorphic sarcoma, dedifferentiated liposarcoma, or angiosarcoma. It aims to see if this treatment can shrink tumors or slow their growth.
This trial tests a two-part treatment for uveal melanoma that has spread to the liver. First, you get a liver-directed chemotherapy (melphalan) through a special procedure called PHP, then you receive an immunotherapy drug (tebentafusp) that helps your immune system attack the cancer.
Hear when a new Uveal Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.